chronic fatigue syndrome: a medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
295 |
4. Check minimum number of eventsNone |
295 |
5. Include endpointsNone |
295 |
6. Filter based on genotype QC (FinnGen only) |
295 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Syndroma lassitudinis postvirale
Similar endpoints
↥List of similar endpoints to
Postviral fatigue syndrome
based on the number of shared cases.
Similar with more cases:
- Cerebral cysts
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1622 | 1089 | 525 |
| Only index persons | 1588 | 1074 | 514 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 34.76 | 35.80 | 32.61 |
| Only index persons | 34.81 | 35.74 | 32.86 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 295 | 236 | 59 |
| Unadjusted period prevalence (%) | 0.07 | 0.08 | 0.03 |
| Median age at first event (years) | 38.57 | 38.56 | 38.60 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 254
- Matched controls
- 2538
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.3
ICD-10 Finland
Postviral fatigue syndrome
+∞
323.0
254
*
R53
ICD-10 Finland
Malaise and fatigue
14.8
78.6
165
282
F48.0
ICD-10 Finland
Neurasthenia
121.5
30.4
32
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.3
29.8
66
92
N06AX16
ATC
venlafaxine; oral
5.5
27.4
95
247
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
12.9
25.9
47
44
TAB00
NOMESCO Finland
Lumbar puncture
14.1
25.4
44
37
Z01.8
ICD-10 Finland
Other specified special examinations
4.8
24.7
100
302
R68.88
ICD-10 Finland
Other specified general symptoms and signs, not elsewhere classified.
60.1
23.6
27
5
N06AX21
ATC
duloxetine; oral
6.4
23.5
68
138
M79.7
ICD-10 Finland
Fibromyalgia
12.1
23.2
43
42
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
9.0
23.1
51
69
N04BC09
ATC
rotigotine; transdermal
251.8
23.0
23
*
N04BC05
ATC
pramipexole; oral
10.9
23.0
45
49
N03AX12
ATC
gabapentin; oral
5.7
22.5
72
165
R50.9
ICD-10 Finland
Fever, unspecified
5.5
22.4
75
181
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.6
20.9
83
240
A04
ICPC
Weakness/tiredness general
5.1
20.8
74
190
XA800
NOMESCO Finland
Neuropsychological investigation
10.4
20.6
41
46
R51.80
ICD-10 Finland
Headache
4.3
20.3
88
276
L28
ICPC
Limited function/disability (L)
6.4
20.1
56
107
M35.7
ICD-10 Finland
Hypermobility syndrome
15.0
19.9
33
25
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
14.4
19.5
33
26
N06AX12
ATC
bupropion; oral
5.6
19.5
62
139
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
41.9
18.9
23
6
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
11.4
18.6
35
35
N03AX16
ATC
pregabalin; oral
4.1
18.2
83
269
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.5
17.3
47
86
A02BA02
ATC
ranitidine; systemic
4.5
16.3
63
172
H03AA01
ATC
levothyroxine sodium; systemic
3.6
16.2
89
333
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.5
15.7
89
338
H02AB06
ATC
prednisolone; systemic
2.9
15.1
141
755
G47.3
ICD-10 Finland
Sleep apnoea
4.0
15.1
67
208
R06.0
ICD-10 Finland
Dyspnoea
3.7
14.8
74
254
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
6.7
14.3
37
63
A02BC05
ATC
esomeprazole; systemic
2.9
14.0
121
610
N06BA07
ATC
modafinil; oral
79.5
13.7
15
*
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
5.4
13.7
42
89
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
19.6
13.6
20
11
M79.0
ICD-10 Finland
Rheumatism, unspecified
10.6
13.6
26
27
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
147.6
13.6
14
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
6.6
13.1
34
58
R42
ICD-10 Finland
Dizziness and giddiness
3.7
13.1
64
214
A28
ICPC
Limited function/disability NOS
6.9
12.8
32
52
N04BD01
ATC
selegiline; oral
73.6
12.7
14
*
R4110
NOMESCO Finland
Physiotherapy
3.1
12.6
84
349
N06AX11
ATC
mirtazapine; oral
2.8
12.6
105
508
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
12.4
127
693
C07AA05
ATC
propranolol; systemic
3.0
12.4
84
355
M79.1
ICD-10 Finland
Myalgia
3.6
12.4
61
204
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
8.3
12.3
27
36
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.8
12.3
103
496
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.6
12.1
31
52
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
4.4
11.9
45
119
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
7.4
11.8
28
42
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
31.7
11.8
15
5
N06AB04
ATC
citalopram; systemic
3.0
11.5
76
312
M54.2
ICD-10 Finland
Cervicalgia
4.9
11.4
38
88
SHA02
NOMESCO Finland
Correction of physiology of bite - basic therapy visit
4.1
11.0
45
128
A02BC02
ATC
pantoprazole; systemic
2.5
11.0
160
1032
XF404
NOMESCO Finland
Ambulatory ECG
5.5
10.8
32
65
H02AB09
ATC
hydrocortisone; systemic
12.0
10.7
19
17
R03AC02
ATC
salbutamol; inhalant
2.5
10.7
164
1078
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
6.6
10.6
27
45
B03BA03
ATC
hydroxocobalamin; parenteral
8.8
10.6
22
27
N06AA09
ATC
amitriptyline; systemic
5.0
10.6
34
76
C07AB07
ATC
bisoprolol; oral
2.7
10.5
86
404
J45.9
ICD-10 Finland
Asthma, unspecified
3.3
10.3
56
200
K30
ICD-10 Finland
Functional dyspepsia
4.0
10.3
42
119
H04.10
ICD-10 Finland
Dry eye syndrome
4.5
10.3
37
93
UJF30
NOMESCO Finland
Ileoscopy through colon
4.2
10.1
39
105
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
10.1
96
490
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
3.6
9.7
46
148
N02AX02
ATC
tramadol; systemic, rectal
2.5
9.7
99
520
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.1
9.7
38
104
J31.0
ICD-10 Finland
Chronic rhinitis
4.0
9.6
39
110
R52.9
ICD-10 Finland
Pain, unspecified
4.3
9.5
35
90
N06BA04
ATC
methylphenidate; oral
6.2
9.5
25
44
G44.0
ICD-10 Finland
Cluster headache syndrome
22.7
9.4
13
6
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
+∞
9.4
9
*
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
5.6
9.4
27
53
G43.9
ICD-10 Finland
Migraine, unspecified
3.6
9.4
43
135
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
9.2
45
148
M03BX01
ATC
baclofen; systemic
12.1
9.2
16
14
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
9.2
35
93
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.4
9.2
46
155
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.9
9.1
61
249
N05BA04
ATC
oxazepam; oral
2.5
9.1
81
394
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.5
9.0
43
139
M25.5
ICD-10 Finland
Pain in joint
2.4
9.0
95
504
C01CA24
ATC
epinephrine; parenteral
3.7
8.9
39
118
A01
ICPC
Pain general/multiple sites
4.3
8.9
33
86
R5140
NOMESCO Finland
Monitoring the use of the aid
4.5
8.9
31
76
R4120
NOMESCO Finland
Occupational therapy
4.9
8.8
28
62
N05CF01
ATC
zopiclone; oral
2.6
8.7
76
362
J01AA02
ATC
doxycycline; systemic
2.4
8.7
193
1445
G44.8
ICD-10 Finland
Other specified headache syndromes
12.2
8.7
15
13
G50.1
ICD-10 Finland
Atypical facial pain
17.0
8.6
13
8
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
4.4
8.6
31
78
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.5
8.6
41
133
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.2
8.5
32
84
G43.3
ICD-10 Finland
Complicated migraine
6.2
8.5
22
38
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
11.3
8.4
15
14
Z01.9
ICD-10 Finland
Special examination, unspecified
5.8
8.4
23
43
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
6.1
8.4
22
39
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
4.1
8.3
32
86
L19
ICPC
Muscle symptom/complaint NOS
9.4
8.2
16
18
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
17.9
8.2
12
7
F32.1
ICD-10 Finland
Moderate depressive episode
3.7
8.1
35
104
N28
ICPC
Limited function/disability (N)
34.6
8.1
10
*
Z71.8
ICD-10 Finland
Other specified counselling
2.3
8.0
88
472
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
8.2
8.0
17
22
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.6
8.0
61
271
R52.2
ICD-10 Finland
Other chronic pain
7.4
7.9
18
26
R03AK11
ATC
formoterol and fluticasone; inhalant
11.3
7.9
14
13
N06AB10
ATC
escitalopram; oral
2.3
7.9
83
435
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.7
7.8
57
244
N03AX11
ATC
topiramate; oral
5.5
7.8
22
43
H02AA02
ATC
fludrocortisone; oral
25.9
7.6
10
*
N99
ICPC
Neurological disease other
25.9
7.6
10
*
J01FA09
ATC
clarithromycin; systemic
2.2
7.6
98
561
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.3
7.6
38
128
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.8
7.5
50
203
R03DC03
ATC
montelukast; oral
2.6
7.5
59
265
R68.81
ICD-10 Finland
A constant or recurrent sensitivity to experience symptoms and signs in relation to common factors in the environment, not elsewhere classified.
+∞
7.3
7
*
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.8
7.3
48
192
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.4
7.2
25
61
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.8
7.2
30
87
R00.2
ICD-10 Finland
Palpitations
3.6
7.2
32
98
I49.9
ICD-10 Finland
Cardiac arrhythmia, unspecified
3.2
7.2
38
133
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
20.7
7.2
10
5
N06AX26
ATC
vortioxetine; oral
3.4
7.2
34
110
SPAT1229
SPAT
Assessment of need for aid
5.2
7.2
21
43
XF402
NOMESCO Finland
ECG with work load test
4.1
7.1
27
72
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.1
7.1
118
749
A03FA01
ATC
metoclopramide; systemic, rectal
2.5
7.1
60
279
G44.2
ICD-10 Finland
Tension-type headache
2.6
7.1
55
243
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.0
7.0
40
147
N05AH04
ATC
quetiapine; oral
2.4
7.0
67
333
U09.9
ICD-10 Finland
Post COVID-19 condition, unspecified
14.3
7.0
11
8
S13.4
ICD-10 Finland
Sprain and strain of cervical spine
4.6
6.9
23
54
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
2.0
6.9
163
1188
M54.5
ICD-10 Finland
Low back pain
2.1
6.9
100
601
AA1AD
NOMESCO Finland
CT of head and brain
2.9
6.8
43
169
N03AE01
ATC
clonazepam; systemic
4.6
6.7
22
51
R03BA08
ATC
ciclesonide; inhalant
3.6
6.7
29
87
UJF92
NOMESCO Finland
Capsular endoscopy
8.2
6.7
14
18
F43.1
ICD-10 Finland
Post-traumatic stress disorder
4.4
6.7
23
56
N06AX17
ATC
milnacipran; oral
12.7
6.6
11
9
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
12.7
6.6
11
9
F41.1
ICD-10 Finland
Generalized anxiety disorder
3.3
6.6
32
105
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.2
6.6
15
22
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.2
6.6
72
382
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
3.4
6.5
30
95
N17
ICPC
Vertigo/dizziness
3.1
6.5
36
129
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
71.6
6.5
7
*
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
71.6
6.5
7
*
J01MA02
ATC
ciprofloxacin; systemic
2.1
6.4
86
493
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.7
6.4
44
182
R11
ICD-10 Finland
Nausea and vomiting
3.3
6.4
31
102
Z02.7
ICD-10 Finland
Issue of medical certificate
3.9
6.4
25
69
F34.1
ICD-10 Finland
Dysthymia
4.0
6.4
24
64
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.0
6.4
19
40
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
6.3
52
239
R51.81
ICD-10 Finland
Facial pain NOS
7.3
6.3
14
20
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.5
6.3
21
50
F90.0
ICD-10 Finland
Disturbance of activity and attention
4.3
6.3
22
55
G90.8
ICD-10 Finland
Other disorders of autonomic nervous system
+∞
6.3
6
*
NXL00
NOMESCO Finland
Biopsy of muscle
27.4
6.3
8
*
U08.9
ICD-10 Finland
Personal history of COVID-19, unspecified
27.4
6.3
8
*
G43.8
ICD-10 Finland
Other migraine
6.0
6.3
16
28
R01AD09
ATC
mometasone; nasal
1.9
6.2
134
929
N29
ICPC
Neurological sympt/complt other
10.4
6.1
11
11
R39.1
ICD-10 Finland
Other difficulties with micturition
10.4
6.1
11
11
M03BC01
ATC
orphenadrine (citrate); systemic
2.1
6.1
77
430
N05CF02
ATC
zolpidem; oral
2.4
6.1
52
243
R20.2
ICD-10 Finland
Paraesthesia of skin
3.5
6.0
27
84
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
161
216
15.21
127.12
2.4
1.8
376.7
368.9
nmol/l
0.20
150
203
141
190
13.30
109.20
2.9
2.1
28.7
19.2
au/ml
—
5
12
66
61
13.65
64.01
1.3
1.3
264.1
165.0
u/ml
2.20
46
37
66
63
13.21
62.66
1.3
1.3
—
—
—
0
0
54
51
12.74
51.24
1.3
1.5
83.7
110.0
u/ml
1.51
24
13
66
83
9.96
51.17
1.8
1.3
—
—
—
0
0
189
683
5.92
50.44
2.1
1.7
97.1
95.3
pmol/l
0.20
106
385
207
841
5.90
47.07
5.5
6.3
1.2
1.2
mmol/l
0.06
179
717
109
264
5.96
45.54
3.0
2.1
16.5
14.5
umol/l
2.04
101
243
97
211
6.36
45.48
2.7
2.2
29.1
25.1
%
2.04
88
183
189
739
5.33
44.25
4.9
6.2
1.2
1.2
mmol/l
0.16
178
684
210
931
5.36
40.97
3.1
2.3
75.6
71.8
nmol/l
1.19
202
871
56
83
8.09
37.50
1.7
1.1
—
—
—
0
0
45
51
10.23
37.30
1.2
1.6
1.0
2.2
e6/l
1.40
35
40
45
51
10.23
37.30
1.3
1.6
14.8
85.8
e6/l
0.84
37
42
115
343
4.86
36.67
1.7
1.6
457.2
48718361.7
pmol/l
0.80
107
312
25
12
22.67
33.28
2.3
3.9
356.6
374.8
u/ml
0.09
25
12
241
1311
5.58
33.25
5.2
2.9
80.8
67.6
ug/l
0.92
235
1245
173
742
4.22
33.09
3.5
4.5
38.0
37.4
g/l
0.73
162
694
94
260
4.84
32.50
3.2
3.6
0.8
0.8
mmol/l
0.36
84
247
33
30
12.26
31.66
1.5
1.9
5.0
5.1
kpa
0.16
33
30
158
662
3.99
30.67
3.1
2.7
—
—
—
0
0
31
27
12.71
30.52
1.1
1.1
—
—
—
0
0
89
256
4.55
28.98
1.6
1.3
89.8
169.9
iu/ml
1.63
37
106
26
19
14.91
28.29
1.1
1.1
—
—
—
0
0
148
623
3.76
27.93
2.0
2.8
2.3
2.3
mmol/l
1.80
137
569
270
1722
7.70
27.85
6.3
3.6
6.2
8.3
mm/h
6.88
264
1611
234
1353
4.53
26.94
8.2
8.7
3.8
3.9
e9/l
0.32
217
1192
29
28
11.38
26.65
1.1
1.1
—
—
—
0
0
206
1112
3.83
25.77
4.2
4.6
5.8
6.3
mmol/l
4.39
189
978
259
1640
5.75
25.72
7.4
6.3
70.4
73.5
u/l
0.55
251
1545
26
25
11.31
23.90
1.0
1.1
—
—
—
0
0
79
244
4.06
22.91
1.9
1.5
1116.5
1073.2
nmol/l
0.16
65
193
104
389
3.58
22.74
1.6
1.3
21.9
20.8
nmol/l
0.31
98
354
44
85
5.91
22.51
1.8
8.4
24.7
25.2
mmol/l
0.64
44
85
22
20
11.81
20.90
1.3
1.2
—
—
—
0
0
119
512
3.22
20.40
3.1
2.5
0.1
0.3
e6/l
3.53
96
383
275
1958
6.97
20.37
6.7
4.2
14.4
14.3
pmol/l
0.61
270
1841
286
2268
9.55
20.03
8.0
4.7
1.6
2.2
mu/l
0.61
279
2160
43
92
5.30
19.62
2.0
2.5
—
—
—
0
0
117
513
3.12
19.22
2.9
2.2
2.2
2.8
mg/l
3.33
101
446
193
1128
3.06
18.65
3.9
2.8
0.0
0.0
estimate
0.00
50
233
47
114
4.71
18.49
2.6
1.7
—
—
—
0
0
194
1146
3.02
18.21
3.9
2.9
0.0
0.0
estimate
0.00
54
232
192
1132
2.99
18.01
5.0
4.0
0.0
0.0
estimate
0.50
53
236
77
277
3.41
17.41
2.5
2.4
3.6
3.6
e6/l
0.01
47
148
19
19
10.62
16.87
1.5
1.6
—
—
—
0
0
149
814
2.68
15.43
3.3
3.1
24.4
28.5
u/l
1.56
143
782
173
1029
2.65
14.89
4.6
5.3
9.2
9.9
umol/l
0.80
161
976
28
53
5.73
14.49
1.3
1.1
—
—
—
0
0
116
579
2.65
14.16
4.1
3.2
0.0
0.0
estimate
1.08
54
238
133
712
2.58
14.03
1.6
1.3
2.6
1.9
u/ml
0.12
48
197
260
1949
3.82
13.82
4.4
3.8
35.6
37.4
mmol/mol
4.20
252
1860
72
283
3.04
13.78
2.0
2.1
2.4
2.4
mmol/l
0.58
58
246
155
899
2.53
13.70
3.8
2.8
—
—
—
0
0
69
266
3.08
13.65
2.3
3.3
883.3
383.0
ng/l
0.37
51
214
107
526
2.62
13.34
2.2
1.8
0.3
0.6
mg/l
9.23
69
383
116
593
2.58
13.34
3.4
2.5
33.7
16.0
ng/l
0.35
32
227
25
51
5.26
11.91
1.2
1.3
—
1.2
—
0
5
14
16
9.14
11.20
1.2
1.0
0.9
1.0
u/l
—
6
9
286
2478
6.05
11.15
18.2
9.3
14.9
18.5
mg/l
1.45
232
1853
67
282
2.78
11.14
3.6
2.7
49.4
238.5
ng/l
1.74
18
145
99
507
2.43
10.99
3.5
2.8
1.0
1.0
kg/l
1.63
14
56
113
616
2.35
10.87
2.8
2.4
53.6
56.4
u/l
0.37
108
577
44
152
3.23
10.34
2.3
2.8
0.2
0.2
g/l
0.18
39
147
19
35
5.73
10.06
1.1
2.1
2.8
2.8
g/l
0.01
13
29
93
480
2.37
10.01
1.4
1.3
24.2
25.2
iu/ml
0.03
18
153
15
22
7.13
9.82
1.1
1.3
—
—
—
0
0
19
36
5.57
9.77
1.1
2.1
3.4
3.6
g/l
0.40
13
28
19
36
5.57
9.77
1.1
2.1
6.4
7.0
g/l
0.82
13
31
19
36
5.57
9.77
1.1
2.1
—
—
—
0
0
11
11
10.35
9.60
1.3
1.0
—
—
—
0
0
91
473
2.34
9.59
1.4
1.3
1.3
11.2
u/ml
1.92
37
201
55
225
2.78
9.57
2.1
2.8
29.6
30.0
s
0.28
55
220
267
2188
3.32
9.15
13.2
7.4
96.8
95.8
ml/min/173m2
0.41
237
1748
263
2151
3.05
8.76
4.0
3.1
5.5
5.6
mmol/l
0.52
253
2028
36
123
3.19
8.58
4.4
10.8
1.0
1.2
inr
—
6
29
13
9
15.04
8.28
1.2
1.4
—
—
—
0
0
10
11
9.37
8.13
1.1
1.0
—
—
%
—
0
0
62
292
2.42
8.03
2.5
2.2
0.6
0.9
e6/l
0.67
33
163
12
8
15.56
7.78
1.1
1.0
—
—
—
0
0
59
281
2.37
7.42
1.6
1.4
22.2
22.0
iu/l
0.01
50
243
33
118
3.02
7.28
3.9
5.7
2.2
1.8
mmol/l
0.27
27
91
10
5
20.62
7.18
1.2
1.0
—
—
—
0
0
10
5
20.62
7.18
1.2
1.2
—
—
—
0
0
13
23
5.87
7.13
1.1
1.2
—
—
—
0
0
13
23
5.87
7.13
1.1
1.2
—
—
—
0
0
13
24
5.62
6.83
1.1
1.2
—
—
—
0
0
13
24
5.62
6.83
1.1
1.2
—
—
—
0
0
13
24
5.62
6.83
1.1
1.2
—
—
—
0
0
263
2225
2.68
6.80
18.7
11.4
13.0
13.4
%
7.34
257
2190
14
28
5.20
6.77
2.9
4.5
155.5
86.3
u/ml
—
5
9
13
25
5.39
6.55
1.2
1.2
—
—
—
0
0
39
162
2.62
6.52
1.9
1.5
—
—
—
0
0
34
132
2.78
6.47
1.4
1.3
8.6
11.1
u/l
0.56
28
107
13
27
4.99
6.03
1.2
1.3
—
—
—
0
0
50
243
2.27
5.96
1.9
1.6
—
—
—
0
0
35
145
2.60
5.88
2.5
1.9
3.7
2.9
mg/l
0.39
24
95
11
20
5.67
5.85
1.2
1.1
161.2
178.9
iu/ml
0.09
11
20
28
105
2.84
5.68
1.3
1.7
—
—
—
0
0
37
162
2.47
5.55
1.9
1.5
—
—
—
0
0
8
5
16.38
5.44
1.1
1.4
—
—
—
0
0
8
5
16.38
5.44
1.0
1.2
—
—
—
0
0
8
5
16.38
5.44
1.1
1.6
—
—
—
0
0
223
1823
1.91
5.41
3.4
2.8
30.3
33.0
u/l
0.38
216
1755
35
156
2.41
5.06
6.9
7.5
104.0
104.5
mmol/l
0.29
35
150
16
50
3.33
4.40
1.7
5.1
59.4
57.2
%
0.26
16
50
21
78
2.82
4.35
1.2
1.6
0.0
0.0
iu/ml
—
9
16
24
96
2.63
4.34
1.7
1.4
—
—
—
0
0
8
9
9.10
4.30
1.6
1.7
26.5
26.2
umol/l
—
8
9
14
41
3.53
4.24
1.1
1.3
—
—
—
0
0
40
204
2.11
4.22
2.7
2.4
29.1
33.1
u/l
0.37
35
170
12
32
3.87
4.13
1.3
1.2
—
—
—
0
0
114
816
1.65
4.04
2.0
1.7
—
—
—
0
0
15
49
3.17
3.86
1.5
4.7
4.1
4.1
e9/l
0.05
15
49
71
452
1.75
3.86
1.7
2.1
294.0
2900.6
umol/l
1.08
64
421
79
526
1.69
3.64
1.5
1.6
1.4
1.4
mmol/l
0.05
67
470
7
9
7.93
3.57
1.0
1.0
—
—
—
0
0
10
28
3.66
3.22
1.0
1.1
—
—
—
0
0
8
15
5.45
3.21
1.0
1.1
2810.7
1642.6
miu/ml
—
8
15
63
408
1.69
3.19
1.8
1.7
1.4
1.3
%
0.32
58
380
21
93
2.35
3.11
1.4
2.2
2.4
5.8
iu/l
—
6
35
21
93
2.35
3.11
1.2
1.1
0.2
2.3
u/ml
—
10
39
14
51
2.83
3.03
1.2
1.0
—
—
—
0
0
5
5
10.14
2.99
1.2
1.2
—
—
—
0
0
7
13
5.48
2.88
1.6
1.2
—
—
—
0
0
14
53
2.72
2.83
5.7
3.6
50.0
52.8
%
0.15
14
53
7
14
5.09
2.74
1.1
1.6
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
14
5.09
2.74
1.4
1.2
—
—
—
0
0
8
19
4.30
2.69
1.3
1.6
5.0
5.4
mmol/l
—
8
19
9
24
3.83
2.69
1.7
1.4
—
—
—
0
0
17
75
2.34
2.56
1.2
1.2
—
—
—
0
0
5
7
7.24
2.56
1.0
1.4
—
—
—
0
0
25
130
2.01
2.54
9.2
12.3
2.0
1.3
mmol/l
0.48
16
107
9
26
3.54
2.50
1.0
1.2
—
—
—
0
0
7
16
4.45
2.49
1.1
1.6
—
—
—
0
0
52
345
1.62
2.39
1.6
1.8
—
—
—
0
0
42
264
1.69
2.37
2.2
2.1
872.4
2955.7
u/l
1.57
14
107
15
65
2.38
2.35
1.6
1.6
—
—
—
0
0
96
735
1.45
2.28
2.2
2.2
—
—
—
0
0
19
93
2.11
2.27
2.3
3.5
1.9
0.8
mmol/l
0.54
14
65
7
18
3.96
2.26
1.1
1.0
15.3
28.8
u/ml
—
7
18
5
9
5.63
2.22
1.2
1.0
—
—
—
0
0
5
9
5.63
2.22
3.8
3.1
—
—
—
0
0
16
74
2.23
2.19
1.1
1.2
—
—
—
0
0
13
55
2.43
2.15
4.8
3.7
25.8
24.7
mmol/l
0.87
13
55
251
2307
1.59
2.14
4.0
3.4
3.0
2.9
mmol/l
1.46
239
2193
87
663
1.44
2.10
2.1
2.0
—
—
—
0
0
40
258
1.64
2.06
2.0
2.6
4.2
5.2
umol/l
0.90
34
217
14
63
2.28
2.04
1.0
1.0
4.0
1.8
u/ml
—
5
33
91
707
1.42
1.96
1.8
1.5
—
—
—
0
0
13
263
0.47
1.95
1.2
1.5
—
—
—
0
0
6
16
3.80
1.94
1.2
1.7
—
—
—
0
0
31
191
1.70
1.90
5.4
4.0
—
—
—
0
0
7
22
3.23
1.89
1.1
1.0
—
—
—
0
0
10
40
2.55
1.85
1.6
1.4
—
—
—
0
0
10
40
2.55
1.85
1.6
1.4
—
—
—
0
0
6
17
3.58
1.84
1.7
1.6
—
—
—
0
0
12
54
2.27
1.76
1.2
1.2
3.2
5.1
u/ml
—
5
21
9
36
2.55
1.75
1.1
1.3
—
—
—
0
0
11
224
0.47
1.70
1.2
1.4
—
—
—
0
0
11
224
0.47
1.70
1.2
1.4
—
—
—
0
0
11
223
0.47
1.68
1.2
1.4
—
—
—
0
0
11
223
0.47
1.68
1.2
1.4
—
—
—
0
0
6
19
3.20
1.67
1.5
1.3
10.4
7.8
u/l
—
6
19
59
439
1.43
1.60
1.6
1.9
—
—
—
0
0
7
26
2.73
1.59
1.4
2.2
—
—
—
0
0
23
138
1.72
1.57
2.5
2.1
78.8
82.0
ml/min/173m2
0.14
13
56
7
27
2.63
1.52
1.1
1.3
—
—
—
0
0
246
2294
1.44
1.51
3.9
3.3
4.9
4.8
mmol/l
0.54
235
2186
31
205
1.57
1.48
2.0
1.6
—
—
—
0
0
9
41
2.23
1.38
1.1
2.0
—
—
—
0
0
23
145
1.64
1.33
3.6
2.5
—
—
—
0
0
244
2287
1.39
1.32
3.8
3.2
1.5
1.5
mmol/l
0.73
232
2177
14
238
0.57
1.26
1.2
1.5
—
—
—
0
0
6
25
2.43
1.25
1.3
1.4
—
—
—
0
0
6
26
2.33
1.19
1.2
1.3
—
—
—
0
0
6
26
2.33
1.19
1.5
1.6
—
—
—
0
0
6
26
2.33
1.19
1.3
1.4
—
—
—
0
0
6
26
2.33
1.19
1.2
1.3
—
—
—
0
0
6
26
2.33
1.19
1.2
1.3
—
—
—
0
0
23
151
1.57
1.15
1.5
1.6
—
—
—
0
0
7
32
2.22
1.09
1.0
1.4
—
—
—
0
0
10
52
1.96
1.07
1.0
1.1
—
—
—
0
0
7
33
2.15
1.06
1.0
1.4
—
—
—
0
0
5
22
2.29
1.04
1.8
1.4
—
—
—
0
0
29
394
0.71
0.98
1.3
1.5
—
—
—
0
0
0
30
0.00
0.98
0.0
2.0
—
263.6
—
0
16
6
27
2.25
0.94
1.2
1.3
—
—
—
0
0
6
27
2.25
0.94
1.2
1.3
—
—
—
0
0
11
63
1.77
0.91
2.2
1.6
—
—
—
0
0
23
161
1.46
0.89
2.2
1.9
24.5
36.2
u/ml
0.46
23
154
6
31
1.95
0.85
1.5
1.1
28.9
36.2
nmol/l
—
6
22
257
2471
1.31
0.81
16.5
10.2
40.9
40.4
%
0.54
221
2109
7
39
1.81
0.73
1.3
1.7
—
—
—
0
0
230
2204
1.20
0.61
3.6
3.0
1.3
1.2
mmol/l
0.26
219
2096
45
382
1.21
0.52
3.2
4.2
31.7
11.5
mg/mmol
0.39
29
256
24
189
1.29
0.51
1.1
1.0
—
—
—
0
0
16
119
1.36
0.49
1.3
1.3
—
—
—
0
0
118
1092
1.13
0.46
3.9
3.9
—
—
—
0
0
56
496
1.16
0.41
1.9
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
9
68
1.33
0.38
2.1
2.0
—
—
—
0
0
12
157
0.75
0.37
1.4
1.4
—
—
—
0
0
12
91
1.33
0.34
1.3
1.6
—
—
—
0
0
15
184
0.81
0.29
1.3
1.5
—
—
—
0
0
8
63
1.28
0.28
1.9
1.8
—
—
—
0
0
31
347
0.88
0.23
1.9
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
10.7
—
37.8
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
16
136
1.19
0.20
1.2
1.5
—
—
—
0
0
22
194
1.14
0.19
1.3
1.4
—
—
—
0
0
230
2270
1.06
0.13
5.0
3.9
—
—
—
0
0
16
142
1.13
0.13
2.4
2.0
—
—
—
0
0
5
48
1.04
0.09
1.6
1.1
—
—
—
0
0
15
137
1.10
0.07
2.4
2.7
23.8
22.1
%
—
6
35
15
155
0.97
0.00
1.4
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
3.8
—
—
—
0
0
0
8
0.00
0.00
0.0
3.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
6.1
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_POSTVIRFAT and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have G6_POSTVIRFAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: G6_POSTVIRFAT – Postviral fatigue syndrome
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data